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Abstract 
 The enhancer of rudimentary gene, e(r), has been found to posses certain amino acids 
with the potential for phosphorylation or ubiquitination. All of these amino acids are highly 
conserved among species. It is possible that any of these sites might play a role in Enhancer of 
Rudimenary Homolog protein, ERH, activation by their respective modifications. This 
possibility has been analyzed through the creation of transgenes with codon changes at the 
identified sites intended to either prevent or mimic phosphorylation or ubiquitination. Upon 
insertion of the e(r) transgenes into the Drosophila melanogaster genome, they have been 
crossed with two lethal and one low viability stock of flies. The location of the e(r) gene on the 
X chromosome allows basic phenotypic observations based on eye color to reveal whether any 
mutations exhibit wild-type ratios of males to females. It has been determined that the 
phosphorylation of Y19, Y22, S47, and Y92 are not necessary in the activation of ERH. 
Likewise, the prevention of ubiquitination at K41 and K90 does not effect protein function. A 
double amino acid change at T18 and S24 in the same transgene has resulted in low viability 
when compared to the wild-type, suggesting a decreased amount of ERH activity as a result of 
this mutation in regards to the Notch signaling pathway. 
Introduction 
 The enhancer of rudimentary gene, e(r), encodes the protein Enhancer of Rudimentary 
Homolog, ERH. This protein is found in many different species such as Homo sapiens (human), 
Drosophila melanogaster (fruit fly), Mus musculus (mouse), and Arabidopsis thaliana 
(flowering weed) (Gelsthorpe et al. 1997). Research is still being done to discover all of the 
activities that ERH may be involved in. However, the most notable action of ERH that has been 
identified so far has been the promotion of the progression and growth of cancer cells in humans. 
Breast cancer cells lines in particular have been shown to possess increased levels of ERH 
(Zafrakas et al. 2008). A similar over expression of the protein has also been shown in the testis 
and ovaries of humans. One of the ways that ERH may specifically aid in cell division within 
tumors is by regulating pyrimidine synthesis (Wojcik et al. 1994). This is an essential process for 
the replication of DNA and therefore cell division and growth. 
 It is evolutionarally significant to note that across species, vertebrates in particular, ERH 
is highly conserved (Gelsthorpe et al. 1997). This conservation lies in the function of the protein 
as well as the amino acid sequence itself. For example, in D. melanogaster, there has been 
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evidence of e(r) gene expression in cells undergoing DNA synthesis and replication. This is 
comparable to the role of e(r) gene expression in human cancer cells. There has also been 
evidence that ERH plays a role in the Notch signaling pathway of D. melanogaster. This 
pathway controls the development of undifferentiated cells and it requires the e(r) gene for 
proper expression. As a result of past studies, it can be said that e(r) positively regulates the 
Notch signaling pathway in Drosophila (Tsubota et al. 2011).  
 In terms of the conservation within the amino acid sequence of ERH, there is strong 
evidence that certain regions and sites are essential for proper function. When comparing the 
human and Drosophila versions of ERH, 76% of the sequence is identical (Fig. 1). By including 
different amino acids that are in the same position and have the same properties, the two proteins 
can be described as 84% similar. Relatively, this is a very high degree of conservation among 
two distinct species.  
 The human and Drosophila ERH are both 104 amino acids in length. The human protein 
has been analyzed by NetPhos. 3.1 (http://www.cbs.dtu.dk/services/NetPhos/) and 
NetphoSitePlus (www.phosphosite.org) and locations of possible phosphorylation or 
ubiquitination have been identified. The possible phosphorylation sites include T18, Y19, Y22, 
S24, S47, and Y92 while the ubiquitination sites may be K41 or K90 (Fig. 2). It is important to 
note that each of these sites are contained within the conserved portions of the protein. One 
exception is that there is a threonine in the Drosophila e(r) gene at the 47th position instead of a 
serine like in the human gene. Although this is not in a conserved portion of the gene, the two 
amino acids do have similar properties. It is common for serine and threonine to be 
interchangebale when it comes to the action of certain kinases. The conservation of the potential 
modification sites suggests that any of these amino acids could be important to proper protein 
function.  
It is possible to study the human e(r) gene within Drosophila based on past research that 
has been done showing that the human ERH and Drosophila ERH are functionally equivalent 
(Tsubota et al. 2016). This means that a sick fruit fly with an e(r) deletion can be rescued with 
the insertion of the human e(r) gene. It is advantageous to study the actual human protein rather 
than a closly matched version of ERH because the results can be directly applied to e(r) function 
in the human body.  
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 To study the hypothesis that one or more of these phosphorylation or ubiquitination sites 
requires modification for ERH to function properly, mutations within the e(r) gene were made. 
Some mutations were designed to prevent modification while others were made to mimic a 
modification, allowing the effects to be analyzed. After insertion of the mutant e(r) gene into 
Drosophila, crosses were done so that the resulting phenotypes could be assessed. The results 
will identify any sites that are required for normal ERH function and activation.  
 There are three mutant phenotypes that were used in order to determine which, if any, 
mutations can successfully rescue. The first is an e(r)27-1 single mutation that causes low 
viability. The mutation lacks the start of transcription as well as 43% of the coding region. The 
second is a lethal e(r)27-1 rhd1 double mutation. The rhd1 mutation causes the development of 
mutant wings. When combined with the e(r)27-1 deletion , the double mutant is lethal. The e(r)37-6 
Nnd-p double mutation is the third one tested. The e(r)37-6 is similar to the e(r)27-1 as it also lacks 
the start of transcription. The combination of e(r)37-6 with a weak Notch allele is lethal. The 
qualifications for “rescue” varies by each mutation. However, as all are X-linked alleles, a ratio 
of males to females possesing a copy of a designed e(r) mutation will reveal the effect of each.  
Methodology 
1. Creation of mutant human coding regions of e(r)  
In order to begin the creation of recombinant vectors with mutations to be studied, mutant 
human e(r) coding regions were designed on paper (Appendix I). The DNA sequences are said to 
be “drosophilized” meaning that some of the amino acid codons were altered so that the most 
frequent codon for each amino acid in the Drosophila genome was used. Certain codons that are 
redundant for amino acids have been proven to be selected for more frequently in the DNA of 
certain species. For example, in humans it is more common to find aspartic acid coded for with 
the bases GAC. In contrast, Drosophila will most often use GAT to code for aspartic acid. By 
using the preferred nucleotides to code for amino acids, the ability of the Drosophila to 
synthesize the mutant protein was ensured but the polypeptide sequence was still consistent with 
that of the human ERH.  
The nine mutants made were: S47A, S47E, Y92F, Y22F, Y19F, T18AS24A, T18ES24A, 
K90R, and K41R (Figs. 1 and 2). The first 7 mutants are testing phosphorylation sites and the 
last two are testing ubiqutination sites. 
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1        10        20        30       40         50        60        70        80        90        100 
·        ·         ·         ·        ·          ·         ·         ·         ·         ·         · 
D. melanogaster wild-type: 
MSHTILLVQPGARPETRTYCDYESVNECMEGVCKIYEEHLKRRNPNTPTITYDISQLFDFIDTMVDISCMVYQKSTNTYAPYNKDWIKEKIYVLLRQAAFSSNT 
Human wild-type: 
MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCLVYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
Phosphorylation Sites:  
T18AS24A: A     A 
T18ES24A: E     A 
Y22F:              F 
S47A:                                       A 
S47E:                                       E 
Y92F:                                     F 
Y19F:           F 
Ubiquitination Sites: 
K41R:                                 R 
K90R:                                          R 
Figure 1. Mutations Studied  
The highlighted regions are conserved between the human and D. melanogaster wild-types. The 
location of each mutation can be seen in the wild-type sequences listed. The mutations and their 
positions are shown below the corresponding wild-type amino acids.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Location of Phosphorylation and Ubiquitination Sites in Crystal Structure  
The crystal structure of the Human ERH with the location of the phosphorylation and 
ubiquitination sites labeled. This figure is a modification of a published figure (Arai et al. 2005).  
 
One type of amino acid change in these mutants is designed to prevent modification. For 
example, positions with tyrosine in the wild-type are potential phosphorylation sites due to the 
prescence of a hydroxyl group (see highlighted hydroxyl in Fig. 3A). To prevent the ability to 
phosphorylate at this site, a mutation is made by replacing tyrosine with phenylalanine. This 
choice has been made because phenylalanine and tyrosine only differ by the hydroxyl group. 
Otherwise, they are similar in size and aromatic properties (Fig. 3A). Following the same logic, 
serine and threonine can also be replaced with alanine which lacks the ability to be 
phosphorylated but maintains a similar size (Fig. 3B). The hydroxyl group capable of being 
phosphorylated in each is also highlighted in Fig. 3B.  
The other type of amino acid change in this study is an amino acid phosphorylation 
mimic. This is able to test the possibility that modification may actually disrupt proper ERH 
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function. An example of this type of mutation would be a change from serine or threonine to 
glutamic acid. Serine and threonine, like tyrosine, have a hydroxyl group that allows 
phosphorylation. Glutamic acid is negatively charged, mimicking a negatively charged 
phosphoryl group on either a serine or threonine. Glutamic acid is also of comparable size to the 
wild-type amino acids when they are phosphorylated (Fig. 3C).  
 
 
A.  
 
 
 
Tyrosine   Phenylalanine  
 
 
B.  
 
 
 
  Serine                    Threonine          Alanine 
 
 
C.  
 
 
 
 
 
 
                 Phosphoserine          Phosphothreonine     Glutamic Acid 
 
Figure 3. Amino Acid Substitutions for Phosphorylation  
A) Phenylalanine is used to replace tyrosine to prevent the possibility of phosphorylation at the 
highlighted hydroxyl group. B) Alanine replaces serine or threonine in some of the mutants to 
prevent phosphorylation at one of the highlighted hydroxyl groups. C) Glutamic acid is used to 
mimic a phosphoserine or phosphothreonine. 
 
The amino acid changes for the proposed ubiquitnation sites are designed to prevent 
modification. The change is arginine substituted for lysine based on evidence that arginine is 
ubiquitination-resistant but resembles lysine in shape and charge (Fig. 4) (Xu and Jaffrey 2013).  
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      Arginine      Lysine 
Figure 4. Amino Acid Substitution for Ubiquitination  
The amino acid arginine which replaces lysine in order to prevent ubiquitination. They are 
similar in charge and size.  
 
 Two of the mutants created contain changes at two sites, 18 and 24. In the Drosophila 
ERH, these two positions have already been shown to be phosphorylated by casein kinase II. 
When both are prevented from phosphorylation, the protein is inactive. However, if only one is 
prevented, phosphorylation is possible and the protein is active. If both sites are replaced by a 
glutamic acid mimic, then ERH becomes inactive (Gelsthorpe et al. 2006). These results will be 
analyzed in the human ERH in the context of this study. 
 In designing the sequences to be sent to Integrated DNA Technologies, Inc. 
(https://www.idtdna.com/site) for synthesis, it was important to consider the species that the final 
vector would be inserted into. Every species has certain codons that they prefer for each amino 
acid and these triplets are used more frequently by the species. By using the preferred codons, it 
was more likely that the Drosophila would be successful in translating the mutated human e(r) 
gene after insertion (Vicario et al. 2007). 
 Another consideration was the ability to eventually create desired sticky ends on both 
sides of the synthesized double-stranded sequence of DNA for cloning the mutant sequences. 
Sticky ends are terminal single-stranded sequences that can base-pair with each other. It was 
decided to have a string of bases followed by a PciI restriction enzyme site, then the start codon 
ATG in the mutant DNA sequences. The other end of the sequence has the completion of the 
coding region followed by a NcoI site and then a few more bases. For both the PciI and NcoI 
sites that were included, the integrity of the sequence encoding the human ERH protein is 
maintained.  
2. Construction of Recombinant Vectors 
The synthesized mutant human e(r) coding regions flanked by PciI and NcoI sites were 
designed in such a way to allow their insertion into a vector called pSmart-empty e(r). This 
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vector was created by adding the 5’ untranslated region and 3’ untranslated region without the 
coding region to a useful research vector called pSmart (Tsubota et al. 2016). At the end of the 5’ 
untranslated portion, a required translation signal, CACC,  is present. In between the two 
untranslated regions, instead of the coding region, is an NcoI site. This enables the insertion of 
any coding region desired, such as the human ERH coding region. Once the pSmart-empty e(r) 
vector was cut with NcoI, while maintaining the translation signal, the synthesized coding region 
was inserted into the proper place.  
Recall that the synthesized mutant coding region has a NcoI site at one end and a PciI site 
at the other. Even though the vector was cut with NcoI, it is possible to insert both ends of the 
coding region into it, thereby making a circular vector. This is due to the fact that the sticky ends 
created by NcoI and PciI are able to base pair together (Fig. 5A and 5B). However, when this 
happens, the resulting sequence can no longer be recognized by either restriction enzyme. This is 
a helpful occurrence because the orientation of the coding region within the vector can be 
checked by locating the NcoI site and the NcoI/PciI site. 
 
A.        NcoI Site         NcoI Sticky End           PciI Sticky End                    PciI Site 
      5’…CCATGG…3’ C .  .  .  .  .              .  CATGT            5’…ACATGT…3’ 
      3’…GGTACC…5’ GGTAC  .              .  .  .  .  . A            3’…TGTACA…5’ 
B.                  NcoI/PciI 
                       5’…CCATGT…3’ 
          3’…GGTACA…5’ 
Figure 5. NcoI and PciI Restriction Enzyme Sites  
A) The site that is recognized by the restriction enzyme NcoI and the sticky end that it creates. 
Likewise, the recognition site and resulting sticky end of PciI. B) The result of the combination 
of an NcoI sticky end and a PciI sticky end that is no longer recognized by either restriction 
enzyme. 
 
 It was important to verify the orientation of the coding region before proceeding to any 
purification steps. There is no way to predict which direction the coding region will insert as 
there is an equal chance for either way to occur. Therefore, a diagnostic digest was done in order 
to check the resulting fragment sizes. The positions of the NcoI/PciI site and NcoI/NcoI sites are 
found with an NcoI-EcoRV double digest. Depending on the fragment sizes, the recombinant 
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plasmid containing the desired orientation can be identified and used for the rest of the procedure 
(Fig. 6).  
A. Desired Orientation 
 
 
 
B. Incorrect Orientation 
 
 
 
 
Figure 6. Digest for Determining Insert Orientation  
A) The resulting fragments when the coding region inserts so that the 5’ untranslated region is 
followed by the beginning of the coding region. B) The resulting fragment when the coding 
region inserts with the end of the coding region after the 5’ untranslated region. This is 
backwards and cannot be used.  
 
To isolate the mutated e(r) gene comprised of the 5’ and 3’ untranslated regions and the 
human coding region, an EcoRI-XhoI double digest was done. These are the two recognition 
sites flanking either end of the untranslated regions within the pSmart plasmid (Fig. 7). The gene 
alone is about 3.0 kb. After running the digest on a gel, an extraction and purification of the band 
at 3.0 kb was done to completely isolate the e(r) gene.  
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Figure 7. pSmart-empty e(r) and Coding Region Insert  
The pSmart vector complete with the 5’ and 3’ untranslated regions and the mutated human 
coding region in between (purple). The coding region insert is represented by a red arrow. 
Important restriction enzyme sites are labeled.  
 
3. Insertion of the Mutated Human e(r) Gene into the Final Vector, pattB 
A realtively new system called jC31 is the chosen method to insert the mutated gene into 
Drosophila. This choice is essential to the phenotypic study and conclusions made following 
insertion into Drosophila embroys because it removes the possibility that the new gene is in a 
different location of the genome in each fly.  
The method that has been used previously for these types of studies utilized P 
transposable elements which insert randomly into the genome (Rubin and Spradling 1982). This 
has caused ambiguity in the results because it is hard to verify whether observations are due to 
the different chromosome locations or the actual mutation that is being studied. In contrast, the 
jC31 system uses jC31 integrase, isolated from Streptomyces temperate bacteriophages, in 
order to perfom site-specific insertion (Thorpe and Smith 1998). jC31 Integrase catalyzes a 
reaction that causes two attachment sites to recombine. 
In order to use this system in Drosophila genetic studies, one attachment site (attP) was 
put into the genome using transposons. A stock of flies is then purified so that every single one 
has the attachment site in the same location. Then, when a plasmid is introduced that also 
pSmart-empty e(r) and coding region insert 
5,193 bp 
Ins
ert
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contains an attachment site (attB) along with jC31 integrase, they can integrate, ensuring that 
the new gene is in the same place in the genome of each resulting embryo (Groth et al. 2004).  
In this specific study, the isolated 3.0 kb mutated human e(r) gene was inserted into a 
plasmid referred to as pattB that was cut with EcoRI and XhoI (Fig. 8). After verifying that this 
insertion was successful, the purified pattB vector with the 3.0 kb insert was sent to BestGene 
Inc (https://www.thebestgene.com) where they perform the jC31 system. They inject jC31 
integrase and the pattB vector sent to them into embryos. Next, they select for the transformants 
(flies that contain the integrated transgene). The transformed stocks are then sent back to Dr. 
Tsubota.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. pattB Vector with e(r) Gene Insert  
The pattB vector with the inserted 3.0 kb e(r) gene (purple) with a mutation in the coding region 
(red arrow). The attachment site (attB) is labeled as well as the mini-white gene that will help in 
identifying the organimsms that contain the plasmid. Important restriction enzyme sites are 
labeled as well.  
 
4. Phenotypic Analysis of Mutant Drosophila Melanogaster Using Genetic Manipulation 
An important aspect of the pattB vector is the mini-white gene that will cause the 
Drosophila containing the vector to have red eyes. Once the flies from BestGene Inc. with the 
vector in their gametes reproduce, those that contain the plasmid in their chromosomes will have 
red eyes, making them identifiable from those that do not (which have white eyes).  
pattB with e(r) insert 
10,465 bp 
Insert 
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To set up crosses that will be used to analyze the effect of the various mutations in the 
e(r) gene, one male with red eyes, thereby containing the transgene, is put with females from a 
heterozygous stock of one of the tested phenotypic mutations. It is important to maintain a 
heterozygous stock because if the Drosophila have an e(r) deletion in both sex chromosomes, 
then they will not survive. However, if the deletion is in only one, then the wild-type gene is 
dominant and the organism survives.  
A Punnett square of the cross is shown in Fig. 9. The males used in the cross have a 
normal X and Y chromosome but the e(r) transgene on both copies of an autosome. The 
transgene is capable of rescuing if a male progeny with an e(r) deletion in their only X 
chromosome results in a functional ERH protein, thereby proving that the mutated copy of e(r) 
on an autosome is functional. If the Drosophila males are in fact rescued by the transgene and 
survive, they will have red eyes. The female progeny will always survive since at least one of 
their X chromosomes will be from the male containing a normal and functional e(r) gene.  
In normal reproduction, there should theoretically be a 1:1 ratio of males to females. In 
this cross, all females that inherit the deletion will survive. By counting the number of these 
females, identified by red eyes, they can be compared to the red-eyed males that are viable. The 
ratio of red-eyed males to females can reveal whether a mutation rescued an e(r) deletion. This is 
the premise of the analyses to determine the viability of each mutation.  
           Heterozygous Female Stock 
            Xe(r)- ; +                   X+; + 
Male with 
Mutated 
e(r) gene 
X+; e(r) 
transgene 
Female 1: 
Xe(r)- /X+;  
+/e(r) transgene 
Female 2: 
X+/ X+; 
+/e(r) transgene 
Y; e(r) 
transgene 
Male 1: 
Xe(r)- /Y;  
+/e(r) transgene 
Male 2: 
X+ /Y;  
+/e(r) transgene 
 
Figure 9. Cross of Heterozygous Female with e(r) Deletion and Male with e(r) Transgene  
The cross between a heterozygous stock of females with a male that contains a mutation to be 
tested. The Punnett square shows the gametes that could come together to create different 
offspring. The contents of the gametes and resulting offspring are shown in the following format: 
sex chromosome(s); autosome allele(s). Female 1 and Male 1 are the ones of interest when 
determining whether each mutation can rescue an e(r) deletion. They can be identified by their 
red eyes, caused by the mini-white gene incorporated in the pattB vector, as opposed to the white 
eyed flies with the wildtype e(r) gene on all sex chromosomes. Note that this is a generalized 
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example that can be applied to each mutant phenotype that was tested (e(r)27-1 rhd1 double 
mutant, e(r)37-6 Nnd-p double mutant, e(r)27-1 single mutant) 
Results 
1. Evidence of the Successful Creation of Recombinant Vectors  
When creating the recombinant vectors containing the mutated human coding region 
within the pSmart vector, there were two different ways that the insert could go into the vector. 
This was due to the fact that both ends of the coding region matched both sticky ends of the 
vector.  In order to determine whether the desired orientation was achieved, a restriction enzyme 
digest was done to differentiate between the two. The enzymes NcoI and EcoRV would create 
the following sized fragments in the two possible cases: 
1) Incorrect Orientation: 0.9 kb and 4.2 kb 
2) Desired Orientation: 1.2 kb and 3.9 kb 
Following the NcoI-EcoRV digest, gel electrophoresis was used to identify the correctly 
orientated cultures. Fig. 10 shows the two cases and evidence that the plasmids used to complete 
the study were in the proper orientation.  
 
 
 
 
 
 
 
 
 
 
Figure 10. Gel Electrophoresis of pSmart Vector with Coding Region Insert  
An example of how the correct orientation of the insert was identified. The plasmid contains the 
human coding region with the mutation Y92F. Lane 1 is not the desired orientation as the lower 
band is below 1 kb, presumably at about 0.9 kb. Lane 2 is the correct orientation as the upper 
band is at approximately 3.9 kb and the lower band is just over 1 kb or approximately 1.2 kb.  
 
After the extraction of the e(r) gene, complete with both untranslated regions and the 
manipulated human coding region, verification of purity and size was necessary. Without proper 
          1       2 
3 kb 
2 kb 
1 kb 
4 kb 
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isolation, the rest of the study would be compromised. The expected band sizes were the 3.0 kb 
fragments of the e(r) gene and the remaining 2.1 kb of the vector. Evidence of successful 
isolation is in Fig. 11.  
 
 
 
 
 
 
 
 
 
Figure 11. Gel Electrophoresis of Isolated e(r) Gene  
An example of successful isolation of the e(r) gene. At about 3.0 kb is the fragment that was 
isolated for the eventual insertion into the pattB vector.  
 
As seen in Fig. 8, once the e(r) gene is inserted into the vector referred to as pattB, the 
entire plasmid is approximately 10.4 kb. A digest with the enzymes XhoI and XbaI can be used 
to verify the total size. The expected sizes of the fragments are 2.0 kb and 8.4 kb. Evidence of 
successful insertion of the e(r) gene is in Fig. 12.  
 
 
 
 
 
 
 
 
Figure 12. Digest of pattB Plasmid and e(r) Gene Insert for Verification  
An example of a digested pattB plasmid containing the insert. The gel is evidence that the vector 
is of correct size and can be inserted into the Drosophila genome.  
 
2. Results of the Crosses of Mutant Females to Males Containing the Designed Transgenes 
The cross described in Fig. 9 was done with each e(r) mutant and all three of the e(r) 
mutant test stocks. The results of the e(r)27-1 single mutant cross with each tested change is 
shown in Table 1. The subsequent crosses of both the e(r)27-1 rhd1 double mutant and e(r)37-6 Nnd-p 
          1   
3 kb 
2 kb 
2 kb 
          1   
8 kb 
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double mutant are shown in Tables 2 and 3. For all three tests, a control was done in order to find 
the ratio of males to females that should be expected. This was done with the same cross but the 
transgene did not have any mutations and was the wild-type human e(r) gene.  
 
Table 1. The e(r)27-1 Mutation Results 
Transgene 
Number of Males 
(Xe(r) 27-1 /Y; 
+/e(r) transgene) 
 
Number of Females 
(Xe(r) 27-1 /X+; 
+/e(r) transgene) 
 
Ratio of 
Males:Females 
Control 245 278 0.881 
T18E S24A 461 555 0.831 
T18A S24A 184 209 0.880 
Y19F 204 229 0.891 
Y22F 292 278 1.05 
S47A 371 388 0.956 
S47E 304 302 1.01 
Y92F 212 220 0.964 
K41R 294 274 1.07 
K90R 273 240 1.14 
Table 1. The cross of each transgene with the e(r)27-1 deletion was done and the number of red-
eyed males and females was counted. A ratio of males to females was calculated for each. The 
control test is included.  
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Table 2. The e(r)27-1 rhd1 Double Mutant Results 
Transgene 
Number of Males 
(Xe(r) 27-1 rhd1 /Y; 
+/e(r) transgene) 
 
Number of Females 
(Xe(r) 27-1 rhd1 /X+; 
+/e(r) transgene) 
 
Ratio of 
Males:Females 
Control 110 297 0.37 
T18E S24A 75 434 0.173 
T18A S24A 91 250 0.364 
Y19F 181 272 0.665 
Y22F 98 308 0.318 
S47A 129 332 0.389 
S47E 90 278 0.324 
Y92F 120 278 0.432 
K41R 150 268 0.560 
K90R 170 201 0.846 
Table 2. A cross of each transgene with the e(r)27-1 rhd1 double mutant was done with the above 
results. A ratio of males to females was calculated for each and the control test is included for 
comparison. 
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Table 3. The e(r)37-6 Nnd-p Double Mutant Results 
Transgene 
Number of Males 
(Xe(r) 37-6 Nnd-p /Y; 
+/e(r) transgene) 
 
Number of Females 
(Xe(r) 37-6 Nnd-p /X+; 
+/e(r) transgene) 
 
Ratio of 
Males:Females 
Control 99 391 0.253 
T18E S24A 4 355 0.011 
T18A S24A 14 339 0.041 
Y19F 112 318 0.352 
Y22F 33 94 0.351 
S47A 208 286 0.727 
S47E 38 71 0.535 
Y92F 94 205 0.459 
K41R 183 320 0.572 
K90R 228 347 0.657 
Table 3. The cross of each transgene with the e(r)37-6 Nnd-p double mutant was done with the 
above results. The ratio of males to females was calculated and the control test is included. 
 
Discussion 
The following mutations appear to exhibit wild-type results across all three tests: Y19F, 
Y22F, S47A, S47E, and Y92F. Relative to the ratio of males to females in the controls, they have 
resulted in rescue. For the changes designed to prevent phosphorylation (Y19F, Y22F, S47A, 
Y92F), this indicates that phosphorylation at these amino acids is not needed in order for the 
protein to work properly. Since the mutation designed to mimic phosphorylation (S47E) was also 
able to rescue, the protein is not inactivated by phosphorylation at serine number 47. Overall, it 
can be said for position 47 that it has no role in protein activation and function when it comes to 
phosphorylation since both the prevention and mimic mutations still resulted in wild-type data.  
The two mutants designed to test the effects of preventing ubiquitination at sites 41 and 
90 resulted in wild-type male to female fly ratios. This means that ubiquitination of either lysine 
is not required for the activity of ERH. Often times, ubiquitination is a means of marking a 
protein for degredation. It could be argued that ERH, with one of these mutations, is more stable 
and is able to remain active longer due to the lack of ubiqutination that may normally occur. 
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However, at this point the affect on the stability of the protein has not been analyzed. Another 
possibility is that ubiqutination is deactivating which needs to be studied futher.  
There are a few possibilities for the results of mutations T18ES24A and T18AS24A. 
They both had significantly lower viability in the e(r)37-6 Nnd-p double mutant cross. This could 
mean that the Notch Signaling pathway in particular relies on activity at one of these two sites. In 
both of the mutations, phosphorylation was prevented at amino acid 24 which suggests that it is 
most likely the amino acid that needs to be phosphorylated for proper function of the Notch 
pathway. Single mutants need to be synthesized for these two sites in order to verify which is 
involved in the Notch pathway. Another possibility was that mimicked phosphorylation at amino 
acid 18 was inactivating the Notch pathway. However, the T18AS24A results prove that this is 
not the case as low viability occurred without a mimic in place of threonine 18. There is yet 
another alternative explanation for the low viability in the e(r)37-6 Nnd-p double mutant cross. 
Perhaps the expression of ERH has been decreased too much by altering the amino acids at these 
positions which is resulting in the low viability that is observed.  
When it comes to the test crosses of the T18 and S24 alterations with the e(r)27-1 rhd1 
double mutant, it is hard to compare the results. This is because the double mutant, which was 
thought to be completely lethal, resulted in the presence of males with white eyes during a later 
round of crosses. This involved the T18AS24A mutant cross. The presence of males surviving 
the “lethal” double mutation adds an extra internal control to those crosses that the others do not 
have. Though the T18ES24A cross with e(r)27-1 rhd1 has almost half the ratio of T18AS24A, they 
cannot be compared properly due to the differences in control.    
Conclusion 
The mutations that have been crossed with all three mutant phenotypes have proven to 
have no effect on the activity of ERH with the exception of T18ES24A and T18AS24A. It has 
been concluded that the serine at position 47 does not have any role in protein activation as the 
prevention or mimic of phosphorylation has shown to produce wild-type results. The tyrosines at 
positions 19, 22 and 92 have also rescued the mutant phenotypes when prevented from 
phosphorylation. However, another study should be done to test the possibility that 
phosphorylation can inactivate ERH. Both of the double amino acid changes at sites 18 and 24 
have shown decreased viability from the wild-type in the e(r)37-6 Nnd-p cross. Reasons for this 
observation may include an interference with the Notch signaling pathway or an overall decrease 
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in protein activity. Although some of these potential phosphorylation sites have proven to have 
no role in protein activation, there may be other reasons for their conservation across species that 
could be further explored in subsequent studies. One potential possibility that can be explored in 
the future is that the amino acids T18, Y19, Y22, and S24 have a redundant function. Since they 
are so close together, it is possible that the phosphorylation of any one of them is enough for 
protein activation. A quadruple mutant with T18A, Y19F, Y22F, and S24A could reveal whether 
this is true in another trial.  
Appendices 
 
I. Human coding region sequences sent to Integrated DNA Technologies, Inc. to be 
synthesized. The coding portion of the DNA sequences starts at the double-underlined 
ATG and ends at the stop codon TAA which is before the double-underlined portion 
at the end. The underlined sequence at the beginning notes the PciI site and the 
underlined sequence at the end notes the NcoI site. Within each sequence is an 
underlined codon change for that particular mutant. The corresponding polypeptide 
sequence has the amino acid change(s) underlined as well.  
 
Phosphorylation Sites 
 
Drosophilized Human e(r) S47A 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACGCCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLKRMNPNAPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
Drosophilized Human e(r) S47E 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACGAGCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLKRMNPNEPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
Drosophilized Human e(r) Y92F 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTTCGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
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MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIFVLLRRQAQQAGK 
 
Drosophilized Human e(r) Y22F 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTTC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTYADFESVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
Drosophilized Human e(r) Y19F 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTTCGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTFADYESVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
Drosophilized Human e(r) T18A S24A 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCGCCTACGCGGACTAC
GAGGCCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRAYADYEAVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
 
Drosophilized Human e(r) T18E S24A 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCGAGTACGCGGACTAC
GAGGCCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGREYADYEAVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
 
Ubiquitination Sites 
 
Drosophilized Human e(r) K90R 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGAAGCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGCGCATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLKRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKERIYVLLRRQAQQAGK 
 
Drosophilized Human e(r) K41R 
ACGGAATTCACATGTCGCACACCATCCTATTGGTACAGCCGACCAAGCGTCCAGAGGGCCGCACCTACGCGGACTAC
GAGAGCGTCAACGAGTGCATGGAGGGCGTGTGCAAGATGTACGAGGAGCACCTGCGCCGCATGAATCCAAACAGCCC
GAGCATTACGTATGACATTAGCCAGCTATTCGATTTCATCGACGATCTGGCGGACCTAAGCTGCCTGGTTTACCGCG
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CTGACACCCAGACCTATCAGCCCTACAATAAGGATTGGATCAAGGAGAAGATCTATGTGCTGCTCCGTCGCCAGGCA
CAGCAGGCTGGCAAGTAACCATGGCTCGAGGAT 
MSHTILLVQPTKRPEGRTYADYESVNECMEGVCKMYEEHLRRMNPNSPSITYDISQLFDFIDDLADLSCL
VYRADTQTYQPYNKDWIKEKIYVLLRRQAQQAGK 
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